Gamida Cell Ltd

NASDAQ:GMDA  
6.81
+0.03 (+0.44%)
Regulatory, Other Pre-Announcement

Gamida Cell Reports Full Year 2020 Financial Results

Published: 03/09/2021 12:50 GMT
Gamida Cell Ltd (GMDA) - Gamida Cell Reports Full Year 2020 Financial Results and Provides Company Update.
Gamida Cell Ltd - on Gda-201, to Submit Company-sponsored Ind Application to FDA and Initiate a Phase 1/2 Clinical Study in Nhl in H2 2021.
Gamida Cell Ltd - for Omidubicel, Expects Bla Submission to FDA in Q4 2021.
Gamida Cell Ltd - Expects Cash Used for Ongoing Operating Activities in 2021 to Range From $100 Million to $120 Million.